Microgen Expands Indications for Russian Botulinum Toxin in Neurology
The only manufacturer of the Russian botulinum toxin type A, SPA Microgen (Naсimbio, Rostec State Corporation) has started clinical trials to expand the indications for Relatox in the treatment of cervical dystonia in patients aged 18 to 65 years.
Cervical dystonia, also called spasmodic torticollis, is the most common form of dystonia. This is a neurological disease characterized by sustained, involuntary, independent contractions of the neck muscles at rest with disabling spasms and pathological postures of the head.
In more than half of cases, patients with spasmodic torticollis have pain in the cervical, occipital, and brachial areas.
According to experts, spasmodic torticollis is the third most prevalent disease among extrapyramidal disorders, after essential tremor and Parkinson's disease. Injection of botulinum toxin type A is one of the most common treatments for this form of dystonia. Its effect is based on blocking the transmission of nerve impulses from nerve to a muscle due to the neurotoxin effect.
Relatox is produced on the full cycle principle in Russia from domestic raw materials and is the only alternative to foreign analogues in the treatment of neurological diseases, which can be managed with botulinum toxin type A. In particular, it is used in blepharospasm and upper extremity spasticity treatment after stroke, and spastic cerebral palsy (CP) in the age group of 12 to 17 years.
According to the results of the European multicenter study, the incidence of primary dystonia in Europe is approximately 15.2 cases per 100,000 population. At the same time, the prevalence of cervical dystonia is estimated to be 5.7 cases per 100,000 population.
Relatox is the first and only domestic botulinum toxin type A. The development of the drug was started by SPA Microgen in 2001. In 2017, the drug was entered into the State Register of Pharmaceutical Products for Medical Purposes on an unlimited basis.